Jubilant Ingrevia: Broke Out after Stake Sell from Promoters

JUBLINGREA Just Broke Out Big after Prabhudas Lilladher gave Hold Rating with a target of Rs 713 and Stake Sell from Promoters

Technical Chart Pattern:
• The stock displays a classic ascending triangle pattern formation spanning from February to June 2025
• Multiple higher lows connected by an ascending trend line (white diagonal support)
• Horizontal resistance zone around ₹735-740 levels acting as the upper boundary
• Recent breakout above the triangle pattern with strong volume confirmation

Key Support and Resistance Levels:
• Primary Support: ₹675-685 (previous resistance turned support)
• Secondary Support: ₹650-660 (trend line support)
• Major Support: ₹535-550 (swing low from March)
• Immediate Resistance: ₹800-810 (psychological level)
• Major Resistance: ₹885 (all-time high marked on chart)

Base Formation Analysis:
• Well-defined base formation between ₹650-740 levels over 4 months
• The consolidation phase showed declining volatility, indicating accumulation
• Multiple tests of resistance at ₹735-740 showing supply absorption
• Base depth of approximately 15-20% from the highs, indicating healthy correction.

Volume Spread Analysis:

Volume Characteristics:
• Significant volume spike during the recent breakout (26.85M vs average 1.75M)
• Volume expansion during upward moves and contraction during pullbacks
• Strong institutional participation is evident from the volume profile
• Volume-price correlation remains positive, supporting the uptrend

Volume Indicators:
• Above-average volume during breakout confirms genuine demand
• Recent sessions show sustained higher volumes, indicating continued interest
• No distribution patterns are visible in volume analysis

Trade Setup:

Entry Strategy:
• Primary Entry: ₹790-800 on any pullback to the breakout zone
• Aggressive Entry: Current market price around ₹799 with tight stops
• Conservative Entry: Wait for retest of ₹740-750 resistance-turned-support
• Scale-in approach recommended given the momentum

Exit Levels:
• Target 1: ₹850 (measuring the triangle height projection)
• Target 2: ₹885 (previous all-time high)
• Target 3: ₹920-950 (extended projection based on base depth)
• Trail stops above ₹850 for position management

Stop Loss Placement:
• Initial Stop Loss: ₹735 (below breakout level)
• Revised Stop Loss: ₹750 (after first target achievement)
• Final Stop Loss: ₹780 (trailing stop for remaining position)

Risk Management Framework:

Position Sizing Guidelines:
• Risk 1-2% of portfolio capital per trade
• Position size calculation: (Account Size × Risk %) ÷ (Entry Price - Stop Loss)
• Maximum position should not exceed 3-5% of the total portfolio
• Consider reducing the size given recent volatility expansion

Risk Control Measures:
• Maintain risk-reward ratio of a minimum of 1:2
• Use partial profit booking at predetermined levels
• Avoid averaging down below stop loss levels
• Monitor sector rotation and market sentiment

Fundamental and Sectoral Backdrop:

Company Overview:
• Jubilant Ingrevia operates in Speciality Chemicals, Nutrition and Health Solutions, and Chemical Intermediates segments
• Global provider serving pharmaceutical, nutrition, agrochemical, and consumer industries with a focus on quality and customization
• Serves 15 of the top 20 Global Pharma & 7 of the top 10 Global Agrochemical companies as a leading low-cost provider

Recent Financial Performance:
• Net profit jumped 153.16% year-over-year to ₹74.05 Cr in Q4 2024-2025
• Q4 2025 revenue of 1,051 cr. down from INR1,074 cr. in Q4 FY24 with EBITDA of INR148 crores showing 42% year-on-year rise
• Market capitalization of 12,664 Cr. with trailing twelve-month revenue of 4,178 Cr.

Sectoral Dynamics:
• The speciality chemicals sector is benefiting from the China+1 strategy
• Increasing demand for pharmaceutical intermediates post-COVID
• The government push for self-reliance in chemical manufacturing
• Export opportunities in agrochemical intermediates are expanding globally

Key Fundamentals:
• The company shows a low return on equity of 9.24% over the last 3 years
• Analyst average share price target of ₹735
• Strong client base with global pharmaceutical and agrochemical giants
• Diversified product portfolio, reducing concentration risk

Market Outlook and Catalysts:

Positive Catalysts:
• Expansion in speciality chemicals capacity
• New product launches in the nutrition segment
• Increasing penetration in international markets
• Potential margin expansion through product mix improvement

Risk Factors:
• Raw material price volatility
• Regulatory changes in target markets
• Currency fluctuation impact on exports
• Competition from Chinese manufacturers

My Take:
This technical setup presents a compelling opportunity with the stock breaking out of a well-defined pattern, supported by strong fundamentals and favourable sector dynamics. The risk-reward profile appears attractive for traders and investors willing to manage position size appropriately.

Keep in the Watchlist.
NO RECO. For Buy/Sell.

📌Thank you for exploring my idea! I hope you found it valuable.

🙏FOLLOW for more
👍BOOST if you found it useful.
✍️COMMENT below with your views.

Meanwhile, check out my other stock ideas on the right side until this trade is activated. I would love your feedback.

Disclaimer: "I am not a SEBI REGISTERED RESEARCH ANALYST AND INVESTMENT ADVISER."
This analysis is intended solely for informational and educational purposes and should not be interpreted as financial advice. It is advisable to consult a qualified financial advisor or conduct thorough research before making investment decisions.